[ad_1]
Hong Kong, July 12, 2021 /PRNewswire/–Akeso, Inc. is pleased to announce that the company’s self-developed second-generation immuno-oncology treatment new drug CD47 monoclonal antibody (AK117) has completed its phase I dose escalation trial. Australia. AK117 did not cause dose-limiting toxicity (DLT) and clinically significant anemia in all subjects in the dose-escalation cohort (once a week (QW) administration 0.3 mg/kg to 45 mg/kg), and was affected by The subjects were well tolerated in all cohorts. No low-dose start is required.
Akso has been approved by the National Medical Products Administration (NMPA) China Initiated a phase Ib/II clinical trial of AK117 combined with azacitidine in the treatment of acute myeloid leukemia (AML). AK117 is the second-generation CD47 monoclonal antibody. Compared with the first-generation CD47 monoclonal antibody, its safety is significantly improved. It is expected that AK117 combined with azacitidine will be better than similar drugs in the treatment of AML. Previous studies on AK117 in myelodysplastic syndrome (MDS) have shown that it has safety advantages, and most patients with MDS have improved hematology when receiving AK117 treatment. So far, clinical…
The full story on Benzinga.com
[ad_2]
Source link
